结核分枝杆菌复合群临床分离株基因组突变与新药及再利用药物表型耐药关联性研究
研究对爱尔兰900株结核分枝杆菌复合群基因组中13个候选基因突变进行筛查,并评估其与贝达喹啉、氯法齐明、利奈唑胺、德拉马尼和普托马尼表型耐药的关联。195株临床分离株携带多样突变,贝达喹啉、德拉马尼和普托马尼耐药株分别仅4、4、2株;所有分离株对利奈唑胺和氯法齐明敏感。作者认为需更多基因型与表型药敏关联研究以扩充耐药突变知识库。
要点
- 900株结核分枝杆菌复合群中195株临床分离株候选基因突变呈高度多样性。
- 贝达喹啉耐药4株,含2株药物敏感结核和2株MDR-TB的Rv0678突变。
- 德拉马尼耐药4株,ddn缺失者高水平耐药且对普托马尼交叉耐药。
核心结论
- 需要更多基因型与表型药敏数据关联的研究来扩充耐药相关突变知识库,尤其针对普托马尼。
- 本研究为未来结核分枝杆菌复合群分离株突变目录的制定提供贡献。
研究设计与样本
- 筛查爱尔兰900株结核分枝杆菌复合群基因组中13个候选基因的突变。
- 评估突变与贝达喹啉、氯法齐明、利奈唑胺、德拉马尼和普托马尼表型耐药的关联。
主要发现
- 195株临床分离株候选基因中鉴定出大量多样性突变,贝达喹啉耐药4株、德拉马尼耐药4株、普托马尼耐药2株。
- 2株药物敏感结核分离株携带Rv0678突变且贝达喹啉耐药。
- 2株MDR-TB分离株携带Rv0678 Met146Thr且贝达喹啉耐药,追溯至2007年,早于贝达喹啉引入。
- 2株ddn缺失分离株高水平德拉马尼耐药且对普托马尼耐药。
- 另2株fbiA突变分离株德拉马尼耐药但未对普托马尼交叉耐药;所有分离株对利奈唑胺和氯法齐明敏感,未发现相关突变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: WGS has the potential to detect resistance-associated mutations and guide treatment of MDR TB. However, the knowledge base to confidently interpret mutations associated with the new and repurposed drugs is sparse, and phenotypic drug susceptibility testing is required to detect resistance. METHODS: We screened 900 Mycobacterium tuberculosis complex genomes from Ireland, a low TB incidence country, for mutations in 13 candidate genes and assessed their association with phenotypic resistance to bedaquiline, clofazimine, linezolid, delamanid and pretomanid. RESULTS: We identified a large diversity of mutations in the candidate genes of 195 clinical isolates, with very few isolates associated with phenotypic resistance to bedaquiline (n = 4), delamanid (n = 4) and pretomanid (n = 2). We identified bedaquiline resistance among two drug-susceptible TB isolates that harboured mutations in Rv0678. Bedaquiline resistance was also identified in two MDR-TB isolates harbouring Met146Thr in Rv0678, which dated back to 2007, prior to the introduction of bedaquiline. High-level delamanid resistance was observed in two isolates with deletions in ddn, which were also resistant to pretomanid. Delamanid resistance was detected in two further isolates that harboured mutations in fbiA, but did not show cross-resistance to pretomanid. All isolates were susceptible to linezolid and clofazimine, and no mutations found were associated with resistance. CONCLUSIONS: More studies that correlate genotypic and phenotypic drug susceptibility data are needed to increase the knowledge base of mutations associated with resistance, in particular for pretomanid. Overall, this study contributes to the development of future mutation catalogues for M. tuberculosis complex isolates.
引用
- Mok S, Roycroft E, Flanagan PR, et al. Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates. J Antimicrob Chemother. 2023. PMID: 37740935. doi:10.1093/jac/dkad252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。